As the first drug approved in nearly 20 years for primary biliary cholangitis, Ocaliva has been priced aggressively at $69,350 a year, but Intercept Pharmaceuticals Inc. CEO Mark Pruzanski believes the drug's safety and efficacy as well at its need in second-line therapy will prove out over time.
Intercept's Pricing Of Ocaliva Anticipates Outcomes Data
With OCA approved for primary biliary cholangitis, Intercept anticipates a potentially slow ramp of sales, but has priced product at $69,350 a year based on need in second-line treatment and in anticipation of survival benefit data.
More from United States
• By
Former Acting FDA Commissioner Sara Brenner is said to have asked Tracy Beth Høeg, new special assistant to the commissioner, to help reexamine the application. Høeg’s position at the agency is raising concerns about the FDA's ongoing approach to vaccine regulation.
• By
Trump announced a 26% reciprocal tariff on India, but a country-agnostic exemption of pharmaceuticals implies that the interests of Indian firms are protected for now. What is Indian pharma’s business exposure and what is domestic industry saying?
• By
As CMS administrator, Mehmet Oz will oversee the second cycle of Medicare drug price negotiations and Part D redesign issues, but will have experienced deputies to help.
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
More from North America
• By
Industry lobbing for pharmaceuticals to be exempt from President Trump’s sweeping US tariffs appears to have paid off.
• By
Calley Means defended reductions in force at the Health and Human Services Department that shocked and outraged federal workers and stakeholders.
• By
Some employees were not impressed with FDA Commissioner Martin Makary's first speech to the agency staff, saying he did not seem to understand the agency's mission.